Increased Secondary Infection in COVID-19 Patients Treated with Steroids in New York City

Steroids are expected to be effective in the treatment of cytokine release syndrome, which is considered to be associated with severe cases of coronavirus disease 2019 (COVID-19). We aimed to investigate the use of steroids and its effects. We conducted a retrospective chart review and an analysis o...

Full description

Saved in:
Bibliographic Details
Published inJapanese Journal of Infectious Diseases Vol. 74; no. 4; pp. 307 - 315
Main Authors Obata, Reiichiro, Maeda, Tetsuro, Rizk, Dahlia, Kuno, Toshiki
Format Journal Article
LanguageEnglish
Published Japan National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee 31.07.2021
Japan Science and Technology Agency
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Steroids are expected to be effective in the treatment of cytokine release syndrome, which is considered to be associated with severe cases of coronavirus disease 2019 (COVID-19). We aimed to investigate the use of steroids and its effects. We conducted a retrospective chart review and an analysis of 226 consecutive hospitalized patients with confirmed COVID-19. Patients were divided into those who received steroids (steroid group) and those who did not (no steroid group). Inverse probability weighted analysis was performed to assess the effect of steroids on in-hospital mortality. The steroid group had higher rates of preexisting hypertension and peripheral vascular disease as well as higher lactate dehydrogenase levels, d-dimer levels, and inflammatory markers than the no steroid group (all P <0.05). The steroid group had significantly higher rates of multifocal pneumonia than the no steroid group at admission (75.4% vs. 50.3%, P = 0.001). Notably, the steroid group had higher rates of developing bacterial infection (25% vs. 13.1%, P = 0.041) and fungal infection (12.7% versus 0.7%, P <0.001) during the hospital course than the no steroid group. After adjustment, it was observed that steroids did not decrease or increase in-hospital mortality (odds ratio [95% confidence interval]: 1.02 [0.60–1.73, P = 0.94]). There was an increase in bacterial and fungal infections with steroid use.
AbstractList Steroids are expected to be effective in the treatment of cytokine release syndrome, which is considered to be associated with severe cases of coronavirus disease 2019 (COVID-19). We aimed to investigate the use of steroids and its effects. We conducted a retrospective chart review and an analysis of 226 consecutive hospitalized patients with confirmed COVID-19. Patients were divided into those who received steroids (steroid group) and those who did not (no steroid group). Inverse probability weighted analysis was performed to assess the effect of steroids on in-hospital mortality. The steroid group had higher rates of preexisting hypertension and peripheral vascular disease as well as higher lactate dehydrogenase levels, d-dimer levels, and inflammatory markers than the no steroid group (all P <0.05). The steroid group had significantly higher rates of multifocal pneumonia than the no steroid group at admission (75.4% vs. 50.3%, P = 0.001). Notably, the steroid group had higher rates of developing bacterial infection (25% vs. 13.1%, P = 0.041) and fungal infection (12.7% versus 0.7%, P <0.001) during the hospital course than the no steroid group. After adjustment, it was observed that steroids did not decrease or increase in-hospital mortality (odds ratio [95% confidence interval]: 1.02 [0.60–1.73, P = 0.94]). There was an increase in bacterial and fungal infections with steroid use.
Since cytokine release syndrome is considered to be associated with severe cases of COVID-19, steroids are expected to be effective for its treatment. We aimed to investigate the use of steroids and its impact. We conducted a retrospective chart review and analysis of 226 consecutive hospitalized patients with confirmed COVID-19. Patients were divided into those who received steroids (steroid group) and those who did not (no steroid group). Inverse weighted probability weighted analysis was performed to assess the effect of steroids for in-hospital mortality. The steroid group had higher rates of preexisting hypertension and peripheral vascular disease than no steroid group and also had higher lactate dehydrogenase, d-dimer, and inflammatory makers compared to no steroid group (all P<0.05). The steroid group had significantly higher rates of multifocal pneumonia than no steroid group at admission (75.4% versus 50.3%, P=0.001). Notably, steroid group had higher rates of bacterial infection (25% versus 13.1%, P=0.041) and fungal infection (12.7% versus 0.7%, P<0.001) during hospital course. After adjustment, steroid did not decrease or increase in-hospital mortality (OR [95% CI]: 1.02 [0.60-1.73, P=0.94]). Steroid did not decrease the in-hospital mortality rate. There were increased bacterial and fungal infections with steroid use.
Steroids are expected to be effective in the treatment of cytokine release syndrome, which is considered to be associated with severe cases of coronavirus disease 2019 (COVID-19). We aimed to investigate the use of steroids and its effects. We conducted a retrospective chart review and an analysis of 226 consecutive hospitalized patients with confirmed COVID-19. Patients were divided into those who received steroids (steroid group) and those who did not (no steroid group). Inverse probability weighted analysis was performed to assess the effect of steroids on in-hospital mortality. The steroid group had higher rates of preexisting hypertension and peripheral vascular disease as well as higher lactate dehydrogenase levels, d-dimer levels, and inflammatory markers than the no steroid group (all P <0.05). The steroid group had significantly higher rates of multifocal pneumonia than the no steroid group at admission (75.4% vs. 50.3%, P = 0.001). Notably, the steroid group had higher rates of developing bacterial infection (25% vs. 13.1%, P = 0.041) and fungal infection (12.7% versus 0.7%, P <0.001) during the hospital course than the no steroid group. After adjustment, it was observed that steroids did not decrease or increase in-hospital mortality (odds ratio [95% confidence interval]: 1.02 [0.60-1.73, P = 0.94]). There was an increase in bacterial and fungal infections with steroid use.Steroids are expected to be effective in the treatment of cytokine release syndrome, which is considered to be associated with severe cases of coronavirus disease 2019 (COVID-19). We aimed to investigate the use of steroids and its effects. We conducted a retrospective chart review and an analysis of 226 consecutive hospitalized patients with confirmed COVID-19. Patients were divided into those who received steroids (steroid group) and those who did not (no steroid group). Inverse probability weighted analysis was performed to assess the effect of steroids on in-hospital mortality. The steroid group had higher rates of preexisting hypertension and peripheral vascular disease as well as higher lactate dehydrogenase levels, d-dimer levels, and inflammatory markers than the no steroid group (all P <0.05). The steroid group had significantly higher rates of multifocal pneumonia than the no steroid group at admission (75.4% vs. 50.3%, P = 0.001). Notably, the steroid group had higher rates of developing bacterial infection (25% vs. 13.1%, P = 0.041) and fungal infection (12.7% versus 0.7%, P <0.001) during the hospital course than the no steroid group. After adjustment, it was observed that steroids did not decrease or increase in-hospital mortality (odds ratio [95% confidence interval]: 1.02 [0.60-1.73, P = 0.94]). There was an increase in bacterial and fungal infections with steroid use.
ArticleNumber JJID.2020.884
Author Maeda, Tetsuro
Kuno, Toshiki
Rizk, Dahlia
Obata, Reiichiro
Author_xml – sequence: 1
  fullname: Obata, Reiichiro
  organization: Department of Medicine, Icahn School of Medicine at Mount Sinai, USA
– sequence: 2
  fullname: Maeda, Tetsuro
  organization: Department of Medicine, Icahn School of Medicine at Mount Sinai, USA
– sequence: 3
  fullname: Rizk, Dahlia
  organization: Department of Medicine, Icahn School of Medicine at Mount Sinai, USA
– sequence: 4
  fullname: Kuno, Toshiki
  organization: Department of Medicine, Icahn School of Medicine at Mount Sinai, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33390434$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtr3DAURkVJaZ6_oFAM3XTjqeQry_KyTPpwCE0hD8hKaOTrRhOPlEgawvz7yp1JoFl0o6vFOZfL9x2SPecdEvKe0VkjJXze-Ht0s7Oz7nRW0YrOpORvyAHLo6wkiL38B85LAZTvk8MYl5RWdc3oO7IPAC3lwA_IbedMQB2xLy7ReNfrsCk6N6BJ1rvCumJ-cdOdlqwtfulk0aVYXGUhZeHJprviMmHwto8T-hOfilsf7ou5TZtj8nbQY8ST3Twi19--Xs1_lOcX37v5l_PS1MBTOYjBCFMxHIwedCuQC7ngRlTAGCxM29YCepRCD5zKfgEtA9FIQRtDa9YIgCPyabv3IfjHNcakVjYaHEft0K-jqnhTU9nQlmb04yt06dfB5etUTqapBGWcZerDjlovVtirh2BXORX1HFoG2i1ggo8x4KCMTXrKKwVtR8WomgpSfwtSU0FqKkjlZrILr9zn9f-3uq21jEn_xhdHh2TNiDun4YpPzz_uC2PudFDo4A_KqK27
CitedBy_id crossref_primary_10_1164_rccm_202110_2317LE
crossref_primary_10_1016_j_cmi_2021_11_008
crossref_primary_10_1038_s41590_021_01091_0
crossref_primary_10_1016_j_intimp_2021_108384
crossref_primary_10_2217_fvl_2021_0244
crossref_primary_10_3390_microorganisms10122372
crossref_primary_10_1097_JCMA_0000000000000764
crossref_primary_10_1183_13993003_03222_2021
crossref_primary_10_21292_2078_5658_2021_18_6_15_21
crossref_primary_10_33073_pjm_2021_039
crossref_primary_10_2478_jccm_2022_0025
crossref_primary_10_17352_2455_5282_000148
crossref_primary_10_3390_ijms241914800
crossref_primary_10_1016_j_idcr_2022_e01656
crossref_primary_10_3390_jcm11072017
crossref_primary_10_1007_s11739_021_02824_7
crossref_primary_10_1016_S2666_5247_22_00355_X
crossref_primary_10_1186_s13018_024_04556_8
crossref_primary_10_7759_cureus_17178
crossref_primary_10_1111_myc_13292
crossref_primary_10_1186_s43162_023_00215_2
crossref_primary_10_2174_2772434417666220720122042
crossref_primary_10_1017_ash_2022_253
crossref_primary_10_3390_jof7110921
crossref_primary_10_3390_life13040907
crossref_primary_10_1002_ccr3_6103
crossref_primary_10_1002_jmv_27393
crossref_primary_10_1016_j_isci_2024_110218
crossref_primary_10_1007_s10157_021_02126_4
crossref_primary_10_3390_antibiotics11081016
crossref_primary_10_1002_phar_2637
crossref_primary_10_4103_ecdt_ecdt_3_22
crossref_primary_10_1186_s43055_022_00700_8
crossref_primary_10_1007_s11239_021_02569_2
crossref_primary_10_1002_jmv_27421
crossref_primary_10_3390_v15091934
crossref_primary_10_37990_medr_1527943
crossref_primary_10_7759_cureus_41054
crossref_primary_10_1371_journal_pone_0309392
crossref_primary_10_3390_biom12050690
crossref_primary_10_4103_ijpm_ijpm_141_22
Cites_doi 10.1001/jama.2020.5394
10.1016/S0140-6736(20)30566-3
10.1136/bmj.m606
10.1164/rccm.201706-1172OC
10.1016/S0140-6736(20)30183-5
10.1001/jamainternmed.2020.0994
10.1001/jama.2016.0287
10.1001/jama.2020.16761
10.1002/jmv.25948
10.1136/bmj.m2426
10.2215/CJN.10181014
10.1056/NEJMcp2009575
10.1056/NEJMoa2021436
10.1136/bmj.m1333
10.1038/s41392-020-0127-9
10.1093/eurheartj/ehaa035
10.1016/j.ijantimicag.2020.105949
10.1136/annrheumdis-2020-217523
10.1056/NEJMoa2001017
10.1001/jama.2020.17021
10.1016/j.cmi.2020.04.040
10.1056/NEJMp1213844
10.1093/cid/ciaa478
10.1016/S0140-6736(20)30317-2
ContentType Journal Article
Copyright 2021 Authors
Copyright Japan Science and Technology Agency 2021
Copyright_xml – notice: 2021 Authors
– notice: Copyright Japan Science and Technology Agency 2021
DBID AAYXX
CITATION
NPM
7QL
7T5
7T7
7TK
7U9
8FD
C1K
FR3
H94
M7N
P64
7X8
DOI 10.7883/yoken.JJID.2020.884
DatabaseName CrossRef
PubMed
Bacteriology Abstracts (Microbiology B)
Immunology Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Neurosciences Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
Virology and AIDS Abstracts
Technology Research Database
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
Immunology Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList Virology and AIDS Abstracts
PubMed

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1884-2836
EndPage 315
ExternalDocumentID 33390434
10_7883_yoken_JJID_2020_884
article_yoken_74_4_74_JJID_2020_884_article_char_en
Genre Journal Article
GeographicLocations United States--US
New York City New York
GeographicLocations_xml – name: New York City New York
– name: United States--US
GroupedDBID ---
.55
29J
2WC
53G
5GY
ACPRK
ADBBV
AENEX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BAWUL
DIK
DU5
E3Z
EBS
EJD
F5P
FRP
GX1
JSF
JSH
KQ8
OK1
RJT
RNS
RZJ
TR2
W2D
X7M
XSB
AAYXX
CITATION
OVT
NPM
7QL
7T5
7T7
7TK
7U9
8FD
C1K
FR3
H94
M7N
P64
7X8
ID FETCH-LOGICAL-c534t-f6fc6c21efcafa96e468b4c623113bc99563de86af408db3913678607c0517633
ISSN 1344-6304
1884-2836
IngestDate Fri Jul 11 10:18:24 EDT 2025
Mon Jun 30 12:03:42 EDT 2025
Thu Jan 02 22:57:45 EST 2025
Tue Jul 01 03:55:16 EDT 2025
Thu Apr 24 23:04:39 EDT 2025
Thu Aug 17 20:33:00 EDT 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords COVID-19
New York
fungal infection
intensive care unit
invasive mechanical ventilation
bacterial infection
steroid
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c534t-f6fc6c21efcafa96e468b4c623113bc99563de86af408db3913678607c0517633
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.jstage.jst.go.jp/article/yoken/74/4/74_JJID.2020.884/_article/-char/en
PMID 33390434
PQID 2557260141
PQPubID 2048383
PageCount 9
ParticipantIDs proquest_miscellaneous_2475087090
proquest_journals_2557260141
pubmed_primary_33390434
crossref_citationtrail_10_7883_yoken_JJID_2020_884
crossref_primary_10_7883_yoken_JJID_2020_884
jstage_primary_article_yoken_74_4_74_JJID_2020_884_article_char_en
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021/07/31
PublicationDateYYYYMMDD 2021-07-31
PublicationDate_xml – month: 07
  year: 2021
  text: 2021/07/31
  day: 31
PublicationDecade 2020
PublicationPlace Japan
PublicationPlace_xml – name: Japan
– name: Tokyo
PublicationTitle Japanese Journal of Infectious Diseases
PublicationTitleAlternate Jpn J Infect Dis
PublicationYear 2021
Publisher National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee
Japan Science and Technology Agency
Publisher_xml – name: National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee
– name: Japan Science and Technology Agency
References 15. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62.
20. Tanne JH. Covid-19: New York City deaths pass 1000 as Trump tells Americans to distance for 30 days. BMJ. 2020;369:m1333.
11. Jangi S. Facing uncertainty--dispatch from Beth Israel Medical Center, Manhattan. N Engl J Med. 2012;367:2267-9.
3. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020;368:m606.
1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-33.
9. National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available at <https://www.covid19treatmentguidelines.nih.gov/>. Accessed September 14, 2020.
17. Capecchi PL, Lazzerini PE, Volterrani L, et al. Antirheumatic agents in covid-19: is IL-6 the right target? Ann Rheum Dis. 2021;80:e2.
21. Murakami N, Siktel HB, Lucido D, et al. Disaster preparedness and awareness of patients on hemodialysis after Hurricane Sandy. Clin J Am Soc Nephrol. 2015;10:1389-96.
10. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2020;ciaa478.
27. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324:1307-16.
2. Religions for Peace. Coronavirus COVID-19 global cases by the Center for Systems Science and Enginerring at Johns Hopkins University. Available at <https://www.rfp.org/resources/coronavirus-covid-19-global-cases-by-the-center-for-systems-science-and-engineering-csse-at-johns-hopkins-university-jhu/>. Accessed April 27, 2021.
14. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:56:105949.
18. Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: a meta-analysis. J Med Virol. 2020;92:2283-5.
7. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934-43.
8. The RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with covid-19 - preliminary report. N Engl J Med. 2021;384:693-704.
25. The Writing Committee for the REMAP-CAP Investigators; Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324:1317-29.
5. Kim GU, Kim MJ, Ra SH, et al. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clin Microbiol Infect. 2020;26:948 e1-948 e3.
12. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801-10.
22. Berlin DA, Gulick RM, Martinez FJ. Severe covid-19. N Engl J Med. 2020;383:2451-60.
23. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473-5.
26. Dequin PF, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324:1298-1306.
19. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323:1574-81.
6. Zhou W, Liu Y, Tian D, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020;5:18.
24. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically Ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018;197:757-67.
13. Hartikainen TS, Sörensen NA, Haller PM, et al. Clinical application of the 4th universal definition of myocardial infarction. Eur Heart J. 2020;41:2209-16.
4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
16. Cleverley J, Piper J, Jones MM. The role of chest radiography in confirming covid-19 pneumonia. BMJ. 2020;370:m2426.
22
23
24
25
26
27
10
11
12
13
14
15
16
17
18
19
1
2
3
4
5
6
7
8
9
20
21
References_xml – reference: 22. Berlin DA, Gulick RM, Martinez FJ. Severe covid-19. N Engl J Med. 2020;383:2451-60.
– reference: 7. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934-43.
– reference: 17. Capecchi PL, Lazzerini PE, Volterrani L, et al. Antirheumatic agents in covid-19: is IL-6 the right target? Ann Rheum Dis. 2021;80:e2.
– reference: 6. Zhou W, Liu Y, Tian D, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020;5:18.
– reference: 12. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801-10.
– reference: 21. Murakami N, Siktel HB, Lucido D, et al. Disaster preparedness and awareness of patients on hemodialysis after Hurricane Sandy. Clin J Am Soc Nephrol. 2015;10:1389-96.
– reference: 25. The Writing Committee for the REMAP-CAP Investigators; Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324:1317-29.
– reference: 1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-33.
– reference: 2. Religions for Peace. Coronavirus COVID-19 global cases by the Center for Systems Science and Enginerring at Johns Hopkins University. Available at <https://www.rfp.org/resources/coronavirus-covid-19-global-cases-by-the-center-for-systems-science-and-engineering-csse-at-johns-hopkins-university-jhu/>. Accessed April 27, 2021.
– reference: 5. Kim GU, Kim MJ, Ra SH, et al. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clin Microbiol Infect. 2020;26:948 e1-948 e3.
– reference: 19. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323:1574-81.
– reference: 8. The RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with covid-19 - preliminary report. N Engl J Med. 2021;384:693-704.
– reference: 9. National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available at <https://www.covid19treatmentguidelines.nih.gov/>. Accessed September 14, 2020.
– reference: 26. Dequin PF, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324:1298-1306.
– reference: 23. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473-5.
– reference: 13. Hartikainen TS, Sörensen NA, Haller PM, et al. Clinical application of the 4th universal definition of myocardial infarction. Eur Heart J. 2020;41:2209-16.
– reference: 4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
– reference: 15. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62.
– reference: 20. Tanne JH. Covid-19: New York City deaths pass 1000 as Trump tells Americans to distance for 30 days. BMJ. 2020;369:m1333.
– reference: 3. Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 2020;368:m606.
– reference: 18. Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: a meta-analysis. J Med Virol. 2020;92:2283-5.
– reference: 10. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2020;ciaa478.
– reference: 11. Jangi S. Facing uncertainty--dispatch from Beth Israel Medical Center, Manhattan. N Engl J Med. 2012;367:2267-9.
– reference: 27. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324:1307-16.
– reference: 14. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:56:105949.
– reference: 16. Cleverley J, Piper J, Jones MM. The role of chest radiography in confirming covid-19 pneumonia. BMJ. 2020;370:m2426.
– reference: 24. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically Ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018;197:757-67.
– ident: 2
– ident: 19
  doi: 10.1001/jama.2020.5394
– ident: 15
  doi: 10.1016/S0140-6736(20)30566-3
– ident: 3
  doi: 10.1136/bmj.m606
– ident: 24
  doi: 10.1164/rccm.201706-1172OC
– ident: 4
  doi: 10.1016/S0140-6736(20)30183-5
– ident: 7
  doi: 10.1001/jamainternmed.2020.0994
– ident: 12
  doi: 10.1001/jama.2016.0287
– ident: 26
  doi: 10.1001/jama.2020.16761
– ident: 18
  doi: 10.1002/jmv.25948
– ident: 9
– ident: 16
  doi: 10.1136/bmj.m2426
– ident: 21
  doi: 10.2215/CJN.10181014
– ident: 22
  doi: 10.1056/NEJMcp2009575
– ident: 8
  doi: 10.1056/NEJMoa2021436
– ident: 20
  doi: 10.1136/bmj.m1333
– ident: 6
  doi: 10.1038/s41392-020-0127-9
– ident: 13
  doi: 10.1093/eurheartj/ehaa035
– ident: 14
  doi: 10.1016/j.ijantimicag.2020.105949
– ident: 17
  doi: 10.1136/annrheumdis-2020-217523
– ident: 1
  doi: 10.1056/NEJMoa2001017
– ident: 27
  doi: 10.1001/jama.2020.17021
– ident: 5
  doi: 10.1016/j.cmi.2020.04.040
– ident: 11
  doi: 10.1056/NEJMp1213844
– ident: 10
  doi: 10.1093/cid/ciaa478
– ident: 23
  doi: 10.1016/S0140-6736(20)30317-2
– ident: 25
SSID ssj0025510
Score 2.4548402
Snippet Steroids are expected to be effective in the treatment of cytokine release syndrome, which is considered to be associated with severe cases of coronavirus...
Since cytokine release syndrome is considered to be associated with severe cases of COVID-19, steroids are expected to be effective for its treatment. We aimed...
SourceID proquest
pubmed
crossref
jstage
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 307
SubjectTerms Bacterial diseases
bacterial infection
Bacterial infections
Confidence intervals
Coronaviruses
COVID-19
Cytokines
Dimers
Eardrum
fungal infection
Fungi
Hypertension
Infections
Inflammation
L-Lactate dehydrogenase
Lactate dehydrogenase
Lactic acid
Mortality
Patients
Secondary infection
Statistical analysis
steroid
Steroid hormones
Steroids
Vascular diseases
Viral diseases
Title Increased Secondary Infection in COVID-19 Patients Treated with Steroids in New York City
URI https://www.jstage.jst.go.jp/article/yoken/74/4/74_JJID.2020.884/_article/-char/en
https://www.ncbi.nlm.nih.gov/pubmed/33390434
https://www.proquest.com/docview/2557260141
https://www.proquest.com/docview/2475087090
Volume 74
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Japanese Journal of Infectious Diseases, 2021/07/31, Vol.74(4), pp.307-315
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELbKQNNeEL8pDGQk3kZGEjtO8ggtsBVGJdSh8hTZTkLDRjMt6QP767lLYreROgS8RFFsx9Hdd_adc_5MyEsZRMgKljtuJLnDtXId6UrMmdJhpLgIVLM0cPJZHJ3yyTyYDwafNrKWVrU61Fdb95X8j1bhGegVd8n-g2btS-EB3IN-4Qoahutf6RiMG3PKwWesMK5NMQPOZFc1GYyj6dfjsePFhj61ahPLTco5kiSURZsSa_mbRkXd-9U7gekUj6nsk0y0nawq84fHuuZTJY1DWhR6UVyW60XvLG1KZlldrdbPx9M2uX5xXsiDL8WV3Tv0cdWcC34wK6tFcVZsLlD4nln5xPmlHVSjiDvgxohtQzaE4Egd8as8y5aHk8nxGGJ23wVN883aIPeLn40WGWOxy7sF0D5Ttim6QW76EDTgeRYf5jbhB2Inz215p7DP11t63CO75h09N-XWD_DUv2fXByGNMzK7Q253UQR900LiLhlky3tk96TLk7hPvllkUIsMapEBd9Qggxpk0A4ZFJFBDTKwKiCDIjIoIuMBOX3_bjY6crpDNBwdMF47uci10L6X5VrmMhYZF2CDGrxez2NK48ZmlmaRkDl3o1SxGDn8IuGGGtnbBGMPyc6yXGaPCYXmQRiylOtYQlgeytBTyg8VRBhMxEE6JL6RWaI7hnk86OQ8gUgTZZ40Mk9Q5gnKPAGZD8kr2-iiJVj5c_W3rTJs5c76usohTzheeo1sHdzJCAPHkOwbRSad7VQJ4CNEfj3uDckLWwyDLf5BAzsDk0p8Dg42zHCxOySPWgDY7zDIeXJtyVOyt7aPfbJTX66yZ-DS1up5g9TfxQqglQ
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increased+secondary+infection+in+COVID-19+patients+treated+with+steroids+in+New+York+City&rft.jtitle=Japanese+journal+of+infectious+diseases&rft.au=Obata%2C+Reiichiro&rft.au=Maeda%2C+Tetsuro&rft.au=DO%2C+Dahlia+Rizk&rft.au=Kuno%2C+Toshiki&rft.date=2021-07-31&rft.eissn=1884-2836&rft_id=info:doi/10.7883%2Fyoken.JJID.2020.884&rft_id=info%3Apmid%2F33390434&rft.externalDocID=33390434
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1344-6304&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1344-6304&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1344-6304&client=summon